Furthermore, HeLa cells derived from cervical cancer and MCF7 cells derived from breast cancer showed significant evidence of SIRT1 ISGylation upon doxorubicin treatment (Supplementary Fig. 7), suggesting that SIRT1 is a bona fide target for ISGylation in a subset of cancer cells. The gene discussed is SIRT1; the disease is breast cancer.